HRP20050053A2 - 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands - Google Patents

1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Info

Publication number: HRP20050053A2
Authority: HR; Croatia
Prior art keywords: cannabinoid; triazole; receptor ligands; carboxamide derivatives; carboxamide
Prior art date: 2002-09-19

Application number

HR20050053A

Other languages

English (en)

Inventor

Josephus

Cornelis

Andrew

Herman

Original Assignee

Solvay Pharmaceuticals B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-19

Filing date

2003-07-19

Publication date

2005-04-30

2003-07-19 Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.

2005-04-30 Publication of HRP20050053A2 publication Critical patent/HRP20050053A2/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Addiction (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

HR20050053A 2002-09-19 2003-07-19 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands HRP20050053A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02078966		2002-09-19
PCT/EP2003/050628 WO2004026301A1 (en)	2002-09-19	2003-09-17	1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Publications (1)

Publication Number	Publication Date
HRP20050053A2 true HRP20050053A2 (en)	2005-04-30

Family

ID=31970417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20050053A HRP20050053A2 (en)	2002-09-19	2003-07-19	1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Country Status (24)

Country	Link
US (1)	US7319110B2 (de)
EP (1)	EP1542678B1 (de)
JP (1)	JP2006501275A (de)
KR (1)	KR100996828B1 (de)
CN (1)	CN1319529C (de)
AR (1)	AR041268A1 (de)
AT (1)	ATE458479T1 (de)
AU (1)	AU2003299024B2 (de)
BR (1)	BR0312020A (de)
CA (1)	CA2491394C (de)
DE (1)	DE60331444D1 (de)
DK (1)	DK1542678T3 (de)
ES (1)	ES2341540T3 (de)
HR (1)	HRP20050053A2 (de)
IL (1)	IL165611A (de)
MX (1)	MXPA05002862A (de)
NO (1)	NO20051870L (de)
PL (1)	PL375020A1 (de)
PT (1)	PT1542678E (de)
RU (1)	RU2325382C2 (de)
SI (1)	SI1542678T1 (de)
UA (1)	UA80298C2 (de)
WO (1)	WO2004026301A1 (de)
ZA (1)	ZA200500133B (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6897240B2 (en) *	2002-05-08	2005-05-24	The Regents Of The University Of California	Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
WO2004094407A1 (ja) *	2003-04-21	2004-11-04	Daiichi Pharmaceutical Co. Ltd.	５員複素環誘導体
US7223780B2 (en) *	2003-05-19	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
WO2005039550A2 (en) *	2003-10-24	2005-05-06	Solvay Pharmaceuticals Gmbh	Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
CN1882327A (zh) *	2003-11-19	2006-12-20	症变治疗公司	含磷的新的拟甲状腺素药
US20060025448A1 (en)	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
FR2874012B1 (fr) *	2004-08-09	2008-08-22	Sanofi Synthelabo	Derives de pyrrole, leur preparation et leur utlisation en therapeutique
ES2255834B1 (es) *	2004-09-14	2008-01-16	Laboratorios Del Dr. Esteve, S.A.	Nuevos derivados 1,2,4-triazol-3-carboxamida.
JP4620123B2 (ja) *	2004-10-01	2011-01-26	エフ．ホフマン−ラロシュアーゲー	ヘキサフルオロイソプロパノール置換エーテル誘導体
AU2005298692A1 (en)	2004-10-25	2006-05-04	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
WO2006050472A2 (en) *	2004-11-03	2006-05-11	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
US20080194656A1 (en) *	2005-04-29	2008-08-14	Monique Jenny Marie Berwaer	Benzotriazole Derivatives as Cannabinoid Receptor Antagonists
CA2613678A1 (en)	2005-06-02	2006-12-07	Glenmark Pharmaceuticals S.A.	Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
TW200726765A (en)	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
JP2008544982A (ja) *	2005-06-29	2008-12-11	アストラゼネカ・アクチエボラーグ	アルファ７ニコチン性受容体調節剤としてのチオフェン−２−カルボキサミド誘導体
EP1910290A2 (de)	2005-06-30	2008-04-16	Prosidion Limited	Gpcr-agonisten
FR2894579B1 (fr) *	2005-12-12	2008-01-18	Sanofi Aventis Sa	Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
EP2081905B1 (de)	2006-07-28	2012-09-12	Boehringer Ingelheim International GmbH	Sulfonyl verbindungen als cb2 rezeptor modulatoren
WO2008033572A1 (en) *	2006-09-15	2008-03-20	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
PE20081849A1 (es)	2007-01-04	2009-01-26	Prosidion Ltd	Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
EA016507B1 (ru)	2007-01-04	2012-05-30	Прозидион Лимитед	Пиперидиновые агонисты gpcr
US20100048632A1 (en)	2007-01-04	2010-02-25	Matthew Colin Thor Fyfe	Piperidine GPCR Agonists
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
CL2008000018A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CN101302200B (zh) *	2007-05-09	2011-04-20	上海医药工业研究院	制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
JP5492092B2 (ja)	2007-11-07	2014-05-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節する化合物
EP2265585B1 (de)	2008-02-21	2014-09-17	Boehringer Ingelheim International GmbH	Amin- und etherverbindungen, die den cb2-rezeptor modulieren
EP2326629B1 (de)	2008-07-10	2013-10-02	Boehringer Ingelheim International GmbH	Den cb2-rezeptor modulierende sulfonverbindungen
WO2010036630A2 (en)	2008-09-25	2010-04-01	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the cb2 receptor
US8629157B2 (en)	2009-01-05	2014-01-14	Boehringer Ingelheim International Gmbh	Pyrrolidine compounds which modulate the CB2 receptor
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
WO2010096371A2 (en)	2009-02-18	2010-08-26	Boehringer Ingelheim International Gmbh	Heterocyclic compounds which modulate the cb2 receptor
US8299103B2 (en)	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja)	2009-06-16	2015-07-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
JP2013505295A (ja)	2009-09-22	2013-02-14	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を選択的に調節する化合物
US9315454B2 (en)	2010-01-15	2016-04-19	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
EP2542539B1 (de)	2010-03-05	2014-02-26	Boehringer Ingelheim International GmbH	Tetrazolverbindungen für selektive cb2-rezeptormodulation
JP5746764B2 (ja)	2010-07-22	2015-07-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節する化合物
CN102558157B (zh) *	2010-12-20	2014-04-30	中国科学院上海药物研究所	羟乙基三唑类化合物或氨乙基三唑类化合物及其制备方法和用途
CN102731418B (zh) *	2012-07-15	2015-03-11	浙江大学	1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
WO2014041106A1 (en) *	2012-09-17	2014-03-20	F. Hoffmann-La Roche Ag	Triazole carboxamide derivatives
EP2803668A1 (de)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole
WO2015188073A1 (en)	2014-06-06	2015-12-10	Research Triangle Institute	Apelin receptor (apj) agonists and uses thereof
AU2016211292B2 (en) *	2015-01-30	2020-05-07	Neurocrine Biosciences, Inc.	Substituted triazoles and methods relating thereto
CN108602806B (zh)	2015-12-09	2022-07-12	研究三角协会	改进的爱帕琳肽受体(apj)激动剂及其用途
JP7104690B2 (ja) *	2016-10-12	2022-07-21	リサーチトライアングルインスティテュート	複素環式アペリン受容体（ａｐｊ）アゴニスト及びそれらの使用
CN113166068B (zh) *	2018-11-20	2024-08-16	上海科技大学	MmpL3抑制剂、组合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58194866A (ja) *	1982-05-07	1983-11-12	Kureha Chem Ind Co Ltd	トリアゾ−ル誘導体及び該誘導体を含有する除草剤
DE3316300A1 (de) *	1982-05-07	1983-11-24	Kureha Kagaku Kogyo K.K., Tokyo	Heribizide zusammensetzung mit einem gehalt an einem derivat des 1,2,4-triazols als wirkstoff
DE3817192A1 (de) *	1988-05-20	1989-11-30	Hoechst Ag	1,2,4-triazolderivate enthaltende pflanzenschuetzende mittel sowie neue derivate des 1,2,4-triazols
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4225778A1 (de) *	1992-08-04	1994-02-17	Hoechst Ag	1,2,4-Triazolyl-3-carbonsäure-4-aminopiperidide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel, insbesondere Fungizide
DE4425144A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Triazolverbindungen und deren Verwendung
FR2741621B1 (fr) *	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2789079B3 (fr) *	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
CA2387892A1 (en)	1999-10-18	2001-04-26	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
WO2001058869A2 (en)	2000-02-11	2001-08-16	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases

2003
- 2003-07-19 HR HR20050053A patent/HRP20050053A2/xx not_active Application Discontinuation
- 2003-09-16 US US10/662,477 patent/US7319110B2/en not_active Expired - Fee Related
- 2003-09-16 AR ARP030103347A patent/AR041268A1/es unknown
- 2003-09-17 MX MXPA05002862A patent/MXPA05002862A/es active IP Right Grant
- 2003-09-17 AT AT03797318T patent/ATE458479T1/de active
- 2003-09-17 EP EP03797318A patent/EP1542678B1/de not_active Expired - Lifetime
- 2003-09-17 AU AU2003299024A patent/AU2003299024B2/en not_active Ceased
- 2003-09-17 KR KR1020057004584A patent/KR100996828B1/ko not_active Expired - Fee Related
- 2003-09-17 PL PL03375020A patent/PL375020A1/xx not_active Application Discontinuation
- 2003-09-17 RU RU2005103244/04A patent/RU2325382C2/ru not_active IP Right Cessation
- 2003-09-17 ES ES03797318T patent/ES2341540T3/es not_active Expired - Lifetime
- 2003-09-17 WO PCT/EP2003/050628 patent/WO2004026301A1/en not_active Ceased
- 2003-09-17 BR BR0312020-1A patent/BR0312020A/pt not_active IP Right Cessation
- 2003-09-17 SI SI200331803T patent/SI1542678T1/sl unknown
- 2003-09-17 JP JP2004537155A patent/JP2006501275A/ja active Pending
- 2003-09-17 DE DE60331444T patent/DE60331444D1/de not_active Expired - Lifetime
- 2003-09-17 UA UAA200503704A patent/UA80298C2/uk unknown
- 2003-09-17 CN CNB038173522A patent/CN1319529C/zh not_active Expired - Fee Related
- 2003-09-17 CA CA2491394A patent/CA2491394C/en not_active Expired - Fee Related
- 2003-09-17 DK DK03797318.7T patent/DK1542678T3/da active
- 2003-09-17 PT PT03797318T patent/PT1542678E/pt unknown
2004
- 2004-12-07 IL IL165611A patent/IL165611A/en not_active IP Right Cessation
2005
- 2005-01-06 ZA ZA200500133A patent/ZA200500133B/en unknown
- 2005-04-18 NO NO20051870A patent/NO20051870L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
UA80298C2 (en)	2007-09-10
US20040106614A1 (en)	2004-06-03
AU2003299024B2 (en)	2008-03-06
US7319110B2 (en)	2008-01-15
ZA200500133B (en)	2005-11-01
DE60331444D1 (de)	2010-04-08
IL165611A0 (en)	2006-01-15
ES2341540T3 (es)	2010-06-22
WO2004026301A1 (en)	2004-04-01
DK1542678T3 (da)	2010-06-07
EP1542678A1 (de)	2005-06-22
JP2006501275A (ja)	2006-01-12
CN1671377A (zh)	2005-09-21
ATE458479T1 (de)	2010-03-15
RU2325382C2 (ru)	2008-05-27
RU2005103244A (ru)	2005-06-27
CA2491394A1 (en)	2004-04-01
CN1319529C (zh)	2007-06-06
PL375020A1 (en)	2005-11-14
IL165611A (en)	2010-04-15
SI1542678T1 (sl)	2010-07-30
NO20051870L (no)	2005-06-03
AU2003299024A1 (en)	2004-04-08
MXPA05002862A (es)	2005-05-27
HK1078796A1 (en)	2006-03-24
AR041268A1 (es)	2005-05-11
BR0312020A (pt)	2005-03-22
KR20050057399A (ko)	2005-06-16
EP1542678B1 (de)	2010-02-24
CA2491394C (en)	2010-06-15
PT1542678E (pt)	2010-05-25
KR100996828B1 (ko)	2010-11-29

Legal Events

Date	Code	Title	Description
2005-04-28	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2005-04-30	A1OB	Publication of a patent application
2010-09-06	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20100906 Year of fee payment: 8
2012-02-07	OBST	Application withdrawn
2025-09-12	A8IS	Corrected front page of an hr-a document

Publication	Publication Date	Title
HRP20050053A2 (en)	2005-04-30	1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
AP2005003368A0 (en)	2005-09-30	PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands.
IL160181A0 (en)	2004-07-25	N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
EG23424A (en)	2005-07-12	Fungicidal azo-carboxamide derivatives.
SI1699795T1 (sl)	2007-10-31	Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
PL377295A1 (pl)	2006-01-23	Pochodne 4,5-diarylotiazolu jako ligandy CB-1
PT1471065E (pt)	2008-03-13	Novos compostos de 1,2,4-triazole
SI1555267T1 (sl)	2013-05-31	2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
ZA200606974B (en)	2008-04-30	Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
AP2005003198A0 (en)	2005-03-31	Spiroindolinepiperidine derivatives.
ZA200500170B (en)	2006-02-22	Indole-3-sulphur derivatives.
ZA200409339B (en)	2006-02-22	Novel benzimidazole derivatives.
SI2308855T1 (sl)	2013-01-31	2,4-diaminopirimidinski derivati
PL376311A1 (en)	2005-12-27	Purine compounds and uses thereof as cannabinoid receptor ligands
AU2003257172A1 (en)	2004-02-25	Cannabinoid receptor ligands
IL164922A0 (en)	2005-12-18	(Imidazol-1-yl-methyl)-pyridazine as nmda receptorblocker
PL373953A1 (en)	2005-09-19	7-amino-benzothiazole derivatives as adenosine receptor ligands
PL369470A1 (en)	2005-04-18	Benzothiazole derivatives as adenosine receptor ligands
ZA200506744B (en)	2006-06-28	PyrazoloÄ1,5-AÜpyrimidine derivatives
AU2003247706A1 (en)	2004-02-16	6, 11-4-carbon bridged erythromycin derivatives
IL164766A0 (en)	2005-12-18	Melanocortin receptor ligands
HRP20040672A2 (en)	2005-08-31	Triazolo-quinolin derivatives useful as adenosine receptor ligands
AU3167402A (en)	2002-06-24	Aminotriazolopyridiine derivatives as adenosine receptor ligands
AU2003294449A1 (en)	2004-06-18	Cannabinoid receptor ligands
ZA200408029B (en)	2005-10-06	Novel 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors.